{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:29:22Z","timestamp":1767140962990,"version":"build-2238731810"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10067-021-05914-1","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T23:34:11Z","timestamp":1632180851000},"page":"5077-5083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib"],"prefix":"10.1007","volume":"40","author":[{"given":"Akihiro","family":"Uchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2363-9803","authenticated-orcid":false,"given":"Takumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Maenohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyasu","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Juji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-9414","authenticated-orcid":false,"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"5914_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jlb.5ri0218-084r","volume":"104","author":"M Gadina","year":"2018","unstructured":"Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y et al (2018) Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol 104:499\u2013514. https:\/\/doi.org\/10.1002\/jlb.5ri0218-084r","journal-title":"J Leukoc Biol"},{"key":"5914_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"5914_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/ard.2008.090068","volume":"68","author":"M Hirao","year":"2009","unstructured":"Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N et al (2009) Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68:654\u2013657. https:\/\/doi.org\/10.1136\/ard.2008.090068","journal-title":"Ann Rheum Dis"},{"key":"5914_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1742-481X.2012.00950.x","volume":"10","author":"R Bootun","year":"2013","unstructured":"Bootun R (2013) Effects of immunosuppressive therapy on wound healing. Int Wound J 10:98\u2013104. https:\/\/doi.org\/10.1111\/j.1742-481X.2012.00950.x","journal-title":"Int Wound J"},{"key":"5914_CR5","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58:1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Rheumatology (Oxford)"},{"key":"5914_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cei.12234","volume":"175","author":"K Migita","year":"2014","unstructured":"Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M et al (2014) Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol 175:208\u2013214. https:\/\/doi.org\/10.1111\/cei.12234","journal-title":"Clin Exp Immunol"},{"key":"5914_CR7","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1096\/fj.00-0073com","volume":"14","author":"RM Gallucci","year":"2000","unstructured":"Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T et al (2000) Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. Faseb j 14:2525\u20132531. https:\/\/doi.org\/10.1096\/fj.00-0073com","journal-title":"Faseb j"},{"key":"5914_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1189\/jlb.0802397","volume":"73","author":"ZQ Lin","year":"2003","unstructured":"Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N (2003) Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 73:713\u2013721. https:\/\/doi.org\/10.1189\/jlb.0802397","journal-title":"J Leukoc Biol"},{"key":"5914_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14397595.2020.1790138","volume":"31","author":"S Okita","year":"2021","unstructured":"Okita S, Ishikawa H, Abe A, Ito S, Nakazono K, Murasawa A et al (2021) Risk factors of postoperative delayed wound healing in patients with rheumatoid arthritis treated with a biological agent. Mod Rheumatol 31:587\u2013592. https:\/\/doi.org\/10.1080\/14397595.2020.1790138","journal-title":"Mod Rheumatol"},{"key":"5914_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14397595.2018.1427431","volume":"28","author":"K Nishida","year":"2018","unstructured":"Nishida K, Harada R, Nasu Y, Takeshita A, Nakahara R, Natsumeda M et al (2018) The clinical course of patients with rheumatoid arthritis who underwent orthopaedic surgeries under disease control by tofacitinib. Mod Rheumatol 28:1063\u20131065. https:\/\/doi.org\/10.1080\/14397595.2018.1427431","journal-title":"Mod Rheumatol"},{"key":"5914_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s10165-012-0683-0","volume":"23","author":"S Momohara","year":"2013","unstructured":"Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A et al (2013) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23:440\u2013449. https:\/\/doi.org\/10.1007\/s10165-012-0683-0","journal-title":"Mod Rheumatol"},{"key":"5914_CR12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2741\/1341","volume":"9","author":"B Conti","year":"2004","unstructured":"Conti B, Tabarean I, Andrei C, Bartfai T (2004) Cytokines and fever. Front Biosci 9:1433\u20131449. https:\/\/doi.org\/10.2741\/1341","journal-title":"Front Biosci"},{"key":"5914_CR13","doi-asserted-by":"publisher","unstructured":"Bari SF, Khan A, Lawson T (2013) C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013.https:\/\/doi.org\/10.1136\/bcr-2013-010423","DOI":"10.1136\/bcr-2013-010423"},{"key":"5914_CR14","doi-asserted-by":"publisher","unstructured":"Berman M, Ben-Ami R, Berliner S, Anouk M, Kaufman I, Broyde A, et al. (2021) The effect of tocilizumab on inflammatory markers in patients hospitalized with serious infections. Case Series and Review of Literature. Life (Basel) 11. https:\/\/doi.org\/10.3390\/life11030258.","DOI":"10.3390\/life11030258"},{"key":"5914_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/art.39996","volume":"69","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C (2017) Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheumatol 69:728\u2013734. https:\/\/doi.org\/10.1002\/art.39996","journal-title":"Arthritis Rheumatol"},{"key":"5914_CR16","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/art.40149","volume":"69","author":"SM Goodman","year":"2017","unstructured":"Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M et al (2017) 2017 American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol 69:1538\u20131551. https:\/\/doi.org\/10.1002\/art.40149","journal-title":"Arthritis Rheumatol"},{"key":"5914_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K et al (2014) Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41:837\u2013852. https:\/\/doi.org\/10.3899\/jrheum.130683","journal-title":"J Rheumatol"},{"key":"5914_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/art.40780","volume":"71","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S et al (2019) Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol 71:685\u2013695. https:\/\/doi.org\/10.1002\/art.40780","journal-title":"Arthritis Rheumatol"},{"key":"5914_CR19","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1213\/ane.0000000000005175","volume":"131","author":"A Margraf","year":"2020","unstructured":"Margraf A, Ludwig N, Zarbock A, Rossaint J (2020) Systemic inflammatory response syndrome after surgery: mechanisms and protection. Anesth Analg 131:1693\u20131707. https:\/\/doi.org\/10.1213\/ane.0000000000005175","journal-title":"Anesth Analg"}],"updated-by":[{"DOI":"10.1007\/s10067-021-05976-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T20:06:33Z","timestamp":1637179593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5914"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05914-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-021-05976-1","URL":"https:\/\/doi.org\/10.1007\/s10067-021-05976-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical committees of the University of Tokyo (No. 2674), Sagamihara National Hospital (No. 2021\u2013013), and JCHO Yugawara Hospital (No. 2021\u20131).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from participants at the University of Tokyo. The boards of Sagamihara National Hospital and JCHO Yugawara Hospital waived the requirement for patients\u2019 informed consent because of the anonymous nature of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ST reports speaker fees and endowments from Pfizer outside the submitted work. The remaining authors have nothing to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}